SM-20302, a Nonpeptide GPIIb/IIIa Receptor Antagonist, Exhibits a Wide Therapeutic Window in a Newly Developed Hemorrhage Model in Mice*

Seiya Horisawa; Munekiyo Kaneko; Teruo Sakurama

doi:10.1055/s-0037-1614908

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 82(06): 1743-1748
DOI: 10.1055/s-0037-1614908

Rapid Communication

Schattauer GmbH

SM-20302, a Nonpeptide GPIIb/IIIa Receptor Antagonist, Exhibits a Wide Therapeutic Window in a Newly Developed Hemorrhage Model in Mice*

Seiya Horisawa

¹From Sumitomo Pharmaceuticals Co., Ltd. Research Center, Osaka, Japan

,

Munekiyo Kaneko

¹From Sumitomo Pharmaceuticals Co., Ltd. Research Center, Osaka, Japan

,

Teruo Sakurama

¹From Sumitomo Pharmaceuticals Co., Ltd. Research Center, Osaka, Japan

› Author Affiliations

Abstract

Summary

We have developed a gastrointestinal hemorrhage model in mice and thereby assessed the potential risk of bleeding following administration of SM-20302, a nonpeptide GPIIb/IIIa receptor antagonist. First, SM-20302 selectively inhibited the interaction between human platelets and fibrinogen in vitro. Second, SM-20302 dose-dependently inhibited ADP-induced ex vivo platelet aggregation in mice and produced an ED₅₀ value of 0.02 mg/kg. ED₅₀ values of cyclo(RGDT)₂, aspirin and ticlopidine were 0.48, 0.74 and 13.3 mg/kg, respectively. Finally, the bleeding risk of SM-20302 was examined in our newly developed hemorrhage model. Gastrointestinal hemorrhage was assessed 24 h later when the antiplatelet agents tested were administered to mice prior to the oral dosing of 0.1 N hydrochloric acid in 90% ethanol. The resulting hemorrhage was classified into three grades, major, minor or no bleeding, primarily based on the criteria used in the TIMI trial. All compounds tested induced gastrointestinal hemorrhage in a dose-dependent manner. Minimum hemorrhagic doses, MHDs, of SM-20302, cyclo (RGDT)₂, aspirin and ticlopidine were 3, 3, 1 and 100 mg/kg, respectively. The potential risk of bleeding was assessed by the ratio of MHD to ED₅₀ value. MHD/ED₅₀ values of SM-20302, cyclo(RGDT)₂, aspirin and ticlopidine were calculated to be 150, 6.3, 1.4 and 7.5, respectively. These results suggest that this experimental hemorrhage model may be useful for the evaluation of the bleeding complications of antiplatelet agents and that SM-20302 may have a wider therapeutic window than nonspecific integrin inhibitor and conventional antiplatelet agents.

Keywords

Platelets - GPIIb/IIIa - SM-20302 - bleeding - mice

Full Text

References

References
1 Rubenstein MD, Wall RT, Baim DS, Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J 1981; 102: 363-7.
2 Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985; 5: 175B-84B.
3 Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
4 Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp specific adhesion receptors. Science 1986; 231: 1559-62.
5 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43.
6 Coller BS, Anderson K, Weisman HF. New antiplatelet agents: Platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-8.
7 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
8 The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
9 The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-8.
10 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
11 The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429-35.
12 The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
13 The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386-95.
14 Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Efforon MB, Topol EJ. on behalf of the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-41.
15 The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
16 The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
17 The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
18 Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM. for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995; 91: 2882-90.
19 Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993; 88 (Suppl. 01) 1512-7.
20 Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. on behalf of the Investigators. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian Lamifiban Study. Circulation 1996; 94: 899-905.
21 Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 1989; 80: 1766-74.
22 Cook NS, Bruttger O, Pally C, Hagenbach A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700, 462, on platelet aggregation and bleeding in guinea-pigs and dogs: Evidence that Ro 43-8857 is orally active. Thromb Haemost 1993; 70: 838-47.
23 O’Laughlin JC, Hoftiezer JW, Mahoney JP, Ivey KJ. Does aspirin prolong bleeding time from gastric biopsies in man?. Gastrointest Endosc 1981; 27: 1-5.
24 Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 1-20.
25 Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-52.
26 Bernardi MM, Califf RM, Kleiman N, Ellis SG, Topol EJ. for the TAMI Study Group. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. Am J Cardiol 1993; 72: 1121-5.
27 Sakurama T, Horisawa S, Kurata H, Kishimoto H, Nakano M, Fukuoka T, Kohda A, Kaneko M. SM-20302, a novel GPIIb/IIIa antagonist, has shown a selective antithrombotic activity without increasing the risk of hemorrhage in vivo. Thromb Haemost. 1997 Supplement: 7.
28 Horisawa S, Kaneko M, Ikeda Y, Ueki Y, Sakurama T. Antithrombotic effect of SM-20302, a nonpeptide GPIIb/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs. Thromb Res 1999; 94: 227-34.
29 Rebello SS, Huang J, Saito K, Lucchesi BR. In vivo efficacy of SM-20302, a GPIIb/IIIa receptor antagonist, correlates with the ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterioscler Thromb Vasc Biol 1998; 18: 954-60.
30 Rebello SS, Huang J, Shiu WJ, Saito K, Kaneko M, Saitoh Y, Lucchesi BR. Pharmacokinetics and pharmacodynamics of SM-20302, a GPIIb/IIIa receptor antagonist, in anesthetized dogs. J Cardiovasc Pharmacol 1998; 32: 485-94.
31 Rebello SS, Huang J, Rosenberg LA, Sakurama T, Kaneko M, Lucchesi BR. SM-20302, a GPIIb/IIIa receptor antagonist, prevents coronary artery thrombosis in a chronic canine model. Eur J Pharmacol 1999; 366: 203-13.
32 Cox D, Motoyama Y, Seki J, Aoki T, Dohi M, Yoshida K. Pentamidine: A non-peptide GPIIb/IIIa antagonist – in vitro studies on platelets from humans and other species. Thromb Haemost 1992; 68: 731-6.
33 Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-95.
34 Howard MA, Firkin BG. Ristocetin – a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-9.
35 Ruoslahti E, Hayman EG, Pierschbacher M, Engvall E. Fibronectin: Purification, immunochemical properties, and biological activities. Methods Enzymol 1982; 82: 803-31.
36 Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 80 10: 2539-47.
37 Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis D, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH. for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991; 115: 256-65.
38 Ginsberg MH, Loftus JC, Plow EF. Cytoadhesions, integrins and platelets. Thromb Haemost 1988; 59: 1-6.
39 Kawamura M, Imura Y, Moriya N, Kita S, Fukushi H, Sugihara H, Nishikawa K, Terashita Z. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: Comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E₁ and argatroban. J Pharm Exp Ther 1996; 277: 502-10.
40 Aoki T, Cox D, Senzaki K, Seki J, Tanaka A, Takasugi H, Motoyama Y. The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIb/IIIa antagonist. Thromb Res 1996; 81: 439-50.
41 Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM. Effect of SR121566A, a potent GPIIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998; 79: 383-8.
42 Savi P, Badorc A, Lale A, Bordes MF, Bornia J, Labouret C, Bernat A, De Cointet P, Hoffmann P, Maffrand JP, Herbert JM. SR121787, a new orally active fibrinogen receptor antagonist. Thromb Haemost 1998; 80: 469-76.
43 Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, De Grado WF, Thoolen MJ, Reilly TM. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 1994; 89: 3-12.
44 Collen D, Lu HR, Stassen JM, Vreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet mediated thrombosis. Thromb Haemost 1994; 71: 95-102.